Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (Nasdaq: ALGS) has announced a portfolio reprioritization focusing on its NASH and COVID-19 programs, particularly ALG-055009 and ALG-097558. The company is reducing its workforce by approximately 10% and has seen a total reduction of 25% since January 2022. This strategic shift aims to maintain a strong balance sheet and extend its cash runway until late 2024. Aligos plans to complete clinical studies for its NASH and chronic hepatitis B programs and collaborate with Merck on NASH research. Financial results for Q4 and year-end 2022 will be reported in mid-March 2023.
Aligos Therapeutics (Nasdaq: ALGS) is on track to complete Phase 2-enabling activities for its thyroid hormone receptor beta drug candidate, ALG-055009, for nonalcoholic steatohepatitis by 2023. Initial Phase 1 data shows favorable pharmacokinetics, indicating potentially more predictable dosing across patients compared to leading competitors. The final Phase 1 cohort is expected to finish in H1 2023, while toxicology studies are projected for completion in H2 2023. A comprehensive pipeline update will be discussed at the J.P. Morgan Healthcare Conference on January 12, 2023.
Aligos Therapeutics has initiated dosing of ALG-125755, a small interfering RNA targeting hepatitis B surface antigen (HBsAg), in chronic hepatitis B (CHB) patients as part of Study ALG-125755-501. This advancement follows successful evaluation in healthy volunteers. The company aims to explore various dosing regimens throughout 2023, potentially identifying a combination therapy regimen. Aligos plans to present study data at scientific conferences this year, highlighting their commitment to innovative treatments for viral and liver diseases.
Aligos Therapeutics (ALGS) announced promising progress in the development of its coronavirus protease inhibitor, ALG-097558, during the 2022 Respi DART meeting. The drug demonstrated significant in vivo antiviral activity and effective viral replication inhibition in human cell cultures. First-in-human trials are expected to commence in H1 2023. CEO Lawrence Blatt highlighted ALG-097558's superior potency against SARS-CoV-2, a favorable profile against mutations, and a predicted dosing regimen without the need for ritonavir boosting. The candidate is being developed with international collaboration.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) presented promising data at The Liver Meeting® (November 4-8, 2022) for its drug candidate ALG-055009, a THR-β agonist targeting nonalcoholic steatohepatitis (NASH). The Phase 1 study showed dose-dependent reductions in triglycerides, LDL, and apolipoprotein B after 14 days of administration in hyperlipidemic subjects. The drug was well tolerated, suggesting a favorable pharmacokinetic profile. Aligos aims to start a Phase 2 study assessing the drug's impact on liver fat reduction. Additionally, new data were presented for drug candidates targeting chronic hepatitis B.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) presents promising data from its Phase 1 study of ALG-000184, a small molecule capsid assembly modulator for chronic hepatitis B (CHB). Key results include reductions in hepatitis B surface antigen levels in subsets of subjects, with three out of seven receiving 300 mg showing reductions of 0.2-0.8 log10 IU/mL. Additionally, all subjects exhibited significant declines in HBV DNA (mean decline of 4.2 log10 IU/mL) and RNA levels (mean decline of 3.1 log10 copies/mL). These findings suggest ALG-000184 might have superior antiviral properties, warranting further study.
Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2022 results with a net loss of $18.6 million, improving from $33.1 million in Q3 2021. Cash and investments totaled $142.3 million, projected to fund operations into H1 2024. Progress was noted in drug candidates targeting chronic hepatitis B (CHB), COVID-19, and NASH. The Company observed favorable safety and antiviral activity for ALG-000184 and initiated longer-term dosing cohorts. ALG-125755 is in evaluation with plans for clinical trials in CHB by Q1 2023. Upcoming presentations at The Liver Meeting (AASLD) are anticipated, showcasing positive data.
Aligos Therapeutics (Nasdaq: ALGS) announced seven poster presentations at The Liver Meeting® on November 4-8, 2022. The presentations will focus on drug candidates for chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH). Key highlights include the promising results of ALG-000184, a capsid assembly modulator showing significant declines in viral markers, and ALG-125755, a siRNA drug candidate in Phase 1 trials. Aligos aims to address unmet medical needs in liver diseases, showcasing its strategic focus on innovative antiviral therapies.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) has announced it will release its third quarter 2022 financial results on November 2, 2022, after U.S. market close. The company focuses on developing innovative therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis (NASH). Founded in 2018, Aligos aims to leverage its expertise to advance its drug pipeline effectively, positioning itself as a leader in these unmet medical needs.
Aligos Therapeutics announced that its pan-Coronavirus inhibitor, ALG-097558, is set to begin clinical studies in the first half of 2023. The company presented its progress at the 20th Annual Discovery on Target Conference in Boston. The drug targets the 3CL protease, which is conserved across coronaviruses, aiming to provide effective treatment against various strains of COVID-19. CEO Lawrence Blatt emphasized the need for therapies that can withstand emerging variants, highlighting the significance of ALG-097558 in addressing unmet medical needs.